Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.
|ClinicalTrials.gov Identifier: NCT00211484|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : May 7, 2007
A compassionate method of treatment is offered to patients where lesions do not meet acceptable criteria for standard therapy. Visudyne (Photodynamic Therapy) and laser photocoagulation treatment (a treatment using heat from a fine point laser beam) have not been found to be effective in treating the lesions these patients have.
Anecortave acetate is an experimental drug that is being tested to prevent the growth of blood vessels under the retina in patients with age-related macular degeneration (AMD).
|Condition or disease||Intervention/treatment||Phase|
|Age-Related Macular Degenerations. Subfoveal Neovascularization.||Drug: Anecortave Acetate||Phase 2|
Manhattan Eye, Ear & Throat Hospital has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||May 2003|
|Study Completion Date :||March 2007|
- This study is designed to provide compassionate use of Anecortave Acetate Sterile Suspension of 15mg for a series of five patients where the lesions do not meet acceptable criteria for standard therapy. [ Time Frame: 24 months ]
- mean change in VA(ETDRS), OCT, FA from baseline to 24 months [ Time Frame: 24 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00211484
|United States, New York|
|Manhattan Eye, Ear & Throat Hospital|
|New York, New York, United States, 10021|
|Principal Investigator:||Jason S. Slakter, MD||Manhattan Eye, Ear & Throat Hospital|